JP2009508511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508511A5 JP2009508511A5 JP2008531733A JP2008531733A JP2009508511A5 JP 2009508511 A5 JP2009508511 A5 JP 2009508511A5 JP 2008531733 A JP2008531733 A JP 2008531733A JP 2008531733 A JP2008531733 A JP 2008531733A JP 2009508511 A5 JP2009508511 A5 JP 2009508511A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- culture
- cell
- hcms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 164
- 238000000034 method Methods 0.000 claims description 67
- 239000002609 medium Substances 0.000 claims description 65
- 238000001964 muscle biopsy Methods 0.000 claims description 42
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 38
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 38
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 31
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 30
- 238000000338 in vitro Methods 0.000 claims description 27
- 230000004069 differentiation Effects 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 19
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 16
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 16
- 102000006783 calponin Human genes 0.000 claims description 15
- 108010086826 calponin Proteins 0.000 claims description 15
- 102100036912 Desmin Human genes 0.000 claims description 14
- 108010044052 Desmin Proteins 0.000 claims description 14
- 210000005045 desmin Anatomy 0.000 claims description 14
- 102000043827 human Smooth muscle Human genes 0.000 claims description 14
- 108700038605 human Smooth muscle Proteins 0.000 claims description 14
- 238000001574 biopsy Methods 0.000 claims description 13
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 12
- 101710099061 Myogenic factor 5 Proteins 0.000 claims description 12
- 102100032970 Myogenin Human genes 0.000 claims description 12
- 108010056785 Myogenin Proteins 0.000 claims description 12
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 claims description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 11
- 239000002953 phosphate buffered saline Substances 0.000 claims description 11
- 210000003205 muscle Anatomy 0.000 claims description 10
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 6
- 230000001114 myogenic effect Effects 0.000 claims description 6
- 229930182831 D-valine Natural products 0.000 claims description 5
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 5
- 210000000107 myocyte Anatomy 0.000 claims description 5
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 5
- 229960004295 valine Drugs 0.000 claims description 5
- 108010081589 Becaplermin Proteins 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 210000003098 myoblast Anatomy 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 229940104230 thymidine Drugs 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- -1 FGFb Proteins 0.000 claims description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 238000004115 adherent culture Methods 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- 210000005068 bladder tissue Anatomy 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 241000287463 Phalacrocorax Species 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 4
- 108010042291 Serum Response Factor Proteins 0.000 description 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004446 Serum Response Factor Human genes 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000037998 chronic venous disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 201000011531 vascular cancer Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150084229 ATXN1 gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100036639 Myosin-11 Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100022056 Serum response factor Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108010055756 hemalin Proteins 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0509557A FR2890977A1 (fr) | 2005-09-19 | 2005-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
| PCT/FR2006/002144 WO2007034069A1 (fr) | 2005-09-19 | 2006-09-19 | Procede d'obtention de cellules musculaires lisses humaines et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009508511A JP2009508511A (ja) | 2009-03-05 |
| JP2009508511A5 true JP2009508511A5 (cg-RX-API-DMAC7.html) | 2012-10-04 |
Family
ID=36587333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008531733A Pending JP2009508511A (ja) | 2005-09-19 | 2006-09-19 | ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090269310A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1934333B9 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009508511A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101310013B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE531791T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006293814B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2622916A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2890977A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL190289A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007034069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2909559B1 (fr) * | 2006-12-06 | 2012-09-07 | Inst Vaisseaux Et Du Sang | Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation |
| KR20180122484A (ko) | 2008-11-04 | 2018-11-12 | 인리젠 | 세포-지지체 구조물 |
| WO2019115790A1 (en) * | 2017-12-14 | 2019-06-20 | Innovacell Biotechnologie Ag | Methods for obtaining muscle derived cells |
| CN112119155A (zh) * | 2018-05-08 | 2020-12-22 | 苏黎士大学 | 用于无异种产生hMPC群的方法 |
| EP3942020B1 (en) * | 2019-03-22 | 2024-05-15 | Innovacell GmbH | Methods for obtaining induced smooth muscle cells |
| JPWO2024143453A1 (cg-RX-API-DMAC7.html) * | 2022-12-28 | 2024-07-04 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2810045B1 (fr) * | 2000-06-07 | 2004-09-03 | Assist Publ Hopitaux De Paris | Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations |
| US20040247575A1 (en) * | 2003-06-03 | 2004-12-09 | Caplice Noel M. | Smooth muscle progenitor cells |
-
2005
- 2005-09-19 FR FR0509557A patent/FR2890977A1/fr not_active Withdrawn
-
2006
- 2006-09-19 WO PCT/FR2006/002144 patent/WO2007034069A1/fr not_active Ceased
- 2006-09-19 AT AT06808166T patent/ATE531791T1/de active
- 2006-09-19 AU AU2006293814A patent/AU2006293814B2/en not_active Ceased
- 2006-09-19 EP EP06808166A patent/EP1934333B9/fr not_active Not-in-force
- 2006-09-19 CN CN2006800428874A patent/CN101310013B/zh not_active Expired - Fee Related
- 2006-09-19 US US12/067,218 patent/US20090269310A1/en not_active Abandoned
- 2006-09-19 CA CA002622916A patent/CA2622916A1/fr not_active Abandoned
- 2006-09-19 JP JP2008531733A patent/JP2009508511A/ja active Pending
-
2008
- 2008-03-19 IL IL190289A patent/IL190289A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7582292B2 (en) | Adipose tissue derived stromal cells for the treatment of neurological disorders | |
| Imanishi et al. | Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats | |
| ES2432744T3 (es) | Células del tejido adiposo extramedular y sus aplicaciones en la reconstitución del tejido cardiaco | |
| US10105395B2 (en) | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease | |
| JP5785287B2 (ja) | 脂肪組織由来細胞の調製方法 | |
| CA2189052A1 (en) | Compositions and method of stimulating the proliferation and differentiation of human fetal and adult pancreatic cells ex vivo | |
| JP2007143554A (ja) | 細胞移植方法及び試薬 | |
| Zhu et al. | Effects of xenogeneic adipose-derived stem cell transplantation on acute-on-chronic liver failure | |
| Kögler et al. | Future of cord blood for non-oncology uses | |
| JP2023133612A (ja) | 膵島移植のための改善された方法 | |
| JP2008528041A (ja) | 内皮細胞の性質を示す脂肪由来成体間質細胞 | |
| JP2022101697A (ja) | ヒト間葉間質細胞の上皮細胞分化 | |
| TW201000110A (en) | Method of differentiating mammalian progenitor cells into insulin producing pancreatic islet cells | |
| EP3277297A1 (en) | Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms | |
| Yang et al. | Nicotinamide facilitates mesenchymal stem cell differentiation into insulin-producing cells and homing to pancreas in diabetic mice | |
| JP2009508511A5 (cg-RX-API-DMAC7.html) | ||
| JP2009508511A (ja) | ヒト平滑筋細胞の獲得方法およびヒト平滑筋細胞の適用 | |
| JP2007519397A (ja) | 新規多能性幹細胞およびその使用 | |
| KR102513507B1 (ko) | 장기 섬유증의 예방 또는 치료제 | |
| EP3013945B1 (en) | Cortical bone-derived stem cells | |
| JP4083024B6 (ja) | 細胞移植方法及び試薬 | |
| Zeng | Swine bone marrow-derived multipotent adult stem cells and its application in swine hearts with postinfarction LV dysfunction |